Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II open-label single-arm multicenter study of Relma-cel in refractory systemic lupus erythematosus
CTR20234152Phase 2Active
- Sponsor
- WuXi AppTec
- Start
- Dec 2023
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of relmacabtagene autoleucel in systemic lupus erythematosus (SLE), sponsored by WuXi AppTec. Started Dec 2023; status: active.
02
Drugs
relmacabtagene autoleucel
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on CTR20234152.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20234152.